Plasma concentrations of non-esterified fatty acids in chronic renal failure in the United Arab Emirates

Saudi Medical Journal

Volumn 25, Issue 11, 2004, Pages 1611-1616

  Gillett, Michael P ^a   Obineche, Enyioma N ^a   Khan, Safina T ^a   Abdulle, Abdishakur M ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHOLESTEROL ESTER; FATTY ACID; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DYSLIPOPROTEINEMIA; FATTY ACID BLOOD LEVEL; FATTY ACID TRANSPORT; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; UNITED ARAB EMIRATES;

ADULT; CHOLESTEROL; CORONARY DISEASE; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; REFERENCE VALUES; RENAL DIALYSIS; RISK FACTORS; SAUDI ARABIA; TRIGLYCERIDES;

EID: 10644238000     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kasiske B. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998; 32 (suppl 3): S142-156.
2. Levey A, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853-906.
3. Wanner C. Importance of hyperlipidaemia and therapy in renal patients. Nephrol Dial Transplant 2000; 15 (suppl 5): S92-96.
4. Gillett MP, Obineche EN, El-Rokhaimi M, Lakhani MS, Abdulle A, Sulaiman M. Lecithin: cholesterol acyltransfer, dyslipoproteinaemia and membrane lipids in uraemia. J Nephrol 2001; 14: 472-480.
5. Senti M, Romero R, Pedro-Botet J, Pelegri A, Nogues X, Rubies-Prat J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992; 41: 1394-1399.
6. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, et al. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 1997; 131: 229-236.
7. Königer M, Quaschning T, Wanner C, Schollmeyer P, Krämer-Guth A. Abnormalities in lipoprotein metabolism in hemodialysis patients. Kidney Int 1999: 56 (suppl 71): S248-250.
8. Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosaya T. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. Kidney Int 1999; 56 (suppl 71): S227-228.
9. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. Impaired high density lipoprotein metabolism in hemodialysis patients. Kidney Int 1992; 41: 1653-1661.
10. Joven J, Villabona C, Vilella E. Pattern of hyperlipoproteinemia in human nephrotic syndrome: influence of renal failure and diabetes mellitus. Nephron 1993; 64: 565-569.
11. Wheeler DC, Bernard DB Lipid abnormalities in the nephrotic syndrome: Causes, consequences and treatment. Am J Kidney Dis 994; 23: 331-346.
12. Chan PC, Persaud J, Varghese Z, Kingstone D, Baillod RA, Moorhead JF. Apolipoprotein B turnover in dialysis patients: Its relationship to pathogenesis of hyperlipidemia. Clin Nephrol 1989; 31: 88-95.
13. Horkko S, Huttunen K, Kasaniemi YA. Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. Kidney Int 1995; 47: 1732-1740.
14. Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int 1999; 56 (suppl 71): S134-136.
15. Bories PC, Subbaihah PV, Bagdade JD. Lecithin: cholesterol acyltransferase activity in dialyzed and undialyzed chronic uremic patients. Nephron 1982; 32: 22-27.
16. McLeeod R, Reeve AE, Frohlich J. Plasma lipoproteins and lecithin: cholesterol acyltransferase distribution in patients on dialysis. Kidney Int 1984; 25: 683-688.
17. Dieplinger H, Schoefeld PY, Fielding CJ. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by haemodialysis or peritoneal dialysis. J Clin Invest 1986; 77: 1071-1083.
18. Gillett MP, Teixeira V, Dimenstein R. Decreased plasma lecithin: cholesterol acyltransfer and associated changes in plasma and red cell lipids in uraemia. Nephrol Dial Transplant 1993; 8: 1071-1083.
19. Spector AA. Fatty acid binding to plasma albumin. J Lipid Res 1975; 16: 165-79.
20. Oliver MF. Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes. Am J Med 2002; 112: 305-311.
21. Jouven X, Charles MA, Desnos M, Ducimetière P. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 2001; 104: 756-761.
22. Carlsson M, Wessman Y, Almgren P, Groop L. High concentrations of nonesterified fatt acids are associated with increased familial risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 2000; 20: 1588-1594.
23. Charles MA, Fontbonne A, Thibult N, Claude JR, Warnet JM, Rosselin G et al. High plasma nonesterified fatty acids are predictive of cancer mortality but not of coronary heart disease mortality: results from the Paris Prospective Study. Am J Epidemiol 2001; 153: 292-298.
24. Pirro M, Mauriege P, Tchernof A, Cantin B, Dagenais GR, Despres JP et al. Plasma free fatty acid concentrations and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis 2002; 160: 377-384.
25. Laszlo A, Nemeth M, Joo I, Kiss E, Havass Z, Szenohradszki P. Changes of serum lipids and lipoproteins during haemodialysis treatment in dialysed chronic uraemic patients. Int Urol Nephrol 1986; 18: 463-470.
26. Mingardi G, Branca E, Cini M, Codegoni bAM, Mecca G, Bizzi A. Factors affecting plasma free fatty acids during hemodialysis. Int J Artif Organs 1988; 11: 95-98.
27. Marangoni R, Civardi F, Savino R, Colombo R, Marangoni F, Mosconi C, et al. Plasma lipids and fatty acid concentrations in chronically uremic patients undergoing blood purification with different methods. Artif Organs 1992; 16: 625-629.
28. Gault MH, Vasdev SC, Longerich L, Purchase L, Sampson C, Johnson E. Heparin, fatty acids and sodium, potassium-ATPase inhibition by plasma factors during hemodialysis. Nephron 1992; 60: 292-301.
29. Bartel LL, Hussey JL, Shrago E. Effect of dialysis on serum carnitine, free fatty acids, and triglyceride concentrations in man and rat. Metabolism 1982; 31: 944-947.
30. Maeda K, Shinzato T, Kobayakawa H. Effects of L-carnitine administration on short-chain fatty acid (acetic acid) and long-chain fatty acid metabolism during hemodialysis. Nephron 1989; 51: 355-361.
31. Perez-Garcia A, Breto M, Alvarino J, Alegre B, Cruz JM. The influence of several factors that intervene in hemodialysis on serum concentrations of triglycerides and free fatty acids. Clin Nephrol 1b] 1979; 12: 14-17.
32. De Smet R, Van Kaer J, Liebich H, Lesaffer G, Verstraete A, Dhondt A, et al. Heparin-induced release of protein-bound solutes during hemodialysis is an in vitro artifact. Clin Chem 2001; 47: 901-909.
33. Nasstrom B, Olivecrona G, Olivecrona. T, Stegmayr BG. Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Scand J Clin Lab Invest 2003; 63: 45-53.
34. Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG. Lipoprotein lipase during continuous heparin infusion: tissue stores become partially depleted. J Lab Clin Med 2001; 138: 206-13.
35. Constantin-Teodusu D, Kirby DP, Short AH, Burden RP, Morgan AG, Greenhaff PL. Free and esterified camitine in continuous ambulatory dialysis patients. Kidney Int 1996; 49: 158-162.
36. Leaf A. Plasma nonesterified fatty acid concentration as a risk factor for sudden cardiac death. Circulation 2001; 104: 744-745.
37. Peters T. All About Albumin: Biochemistry, Genetics and Medical Applications. San Diego (CA): Academic Press; 1995.
38. Bhattacharya AA, Grunt T, Cuny S. Crystallographic analysis reveals common modes of binding of medium- and long-chain fatty acids to human senim albumin. J Mol Biol 2000; 303: 721-732.
39. Choi JK, Ho J, Curry S, Qin D, Bittman R, Hamilton JA. Interactions of very long-chain saturated fatty acids with serum albumin. J Lipid Res 2002; 43: 1000-1010.
40. Hamilton JA, Cistola DP, Morriset JD, Sparrow JT, Small DM. Interactions of myristic acid with bovine serum albumin: a 13C NMR study. Proc Natl Acad Sci USA 1984; 81: 3718-3722.